查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1928660

第三方医疗保健市场按服务类型、交付管道、所有权类型、支付类型和最终用户类型分類的全球预测（2026-2032 年）

Third-party Medical Institutions Market by Service Type, Delivery Channel, Ownership Model, Payment Model, End User Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，第三方医疗保健提供者市场价值将达到 74.3 亿美元，到 2026 年将成长至 80.7 亿美元，复合年增长率为 8.91%，到 2032 年将达到 135.2 亿美元。

关键市场统计数据
基准年 2025 74.3亿美元
预计年份：2026年 80.7亿美元
预测年份 2032 135.2亿美元
复合年增长率 (%) 8.91%

权威指南阐述了第三方服务提供者在现代医疗保健服务中的策略重要性、范围和相关人员相关性。

现代医疗保健环境瞬息万变，第三方服务提供者在拓展医疗服务能力、提供专科护理服务以及支援整合式医疗路径方面发挥日益重要的作用。本导言阐明了报告的定位，并介绍了研究的策略目标，旨在为管理或依赖外包临床服务、诊断平台、居家医疗服务和替代支付方式的相关人员提供参考。导言强调了高品质、可操作的资讯对于支援筹资策略、伙伴关係评估以及在各种医疗服务提供者和支付方环境中的营运设计的重要性。

对重塑第三方医疗服务提供者的结构和技术力量进行全面分析，并探讨这些力量将如何重新定义临床和经营模式。

医疗保健领域正经历着一场由技术应用、政策演变和患者期望变化所驱动的变革。这些变化正在重塑第三方医疗机构的营运模式。其中一个关键驱动因素是虚拟医疗和远端医疗的兴起，这不仅拓展了远端医疗和居家医疗服务的范围，也迫使诊断和门诊医疗服务提供者将数位化工作流程和远端监测融入其核心服务中。同时，诊断影像技术的进步正在提升非侵入性检查的临床效用，重塑门诊和住院领域的转诊模式和投资重点。

对近期美国关税对外包临床服务提供者的采购、供应商策略和资本规划的影响进行基于证据的评估

美国近期推出的关税政策对依赖跨境医疗设备、耗材和技术服务的医疗机构的供应链、采购经济效益和策略采购决策产生了累积影响。其影响远不止价格调整；关税还波及采购计画、供应商关係及资本投资方案。为此，医疗机构及其供应商合作伙伴正在加快供应链风险评估，并将采购重点重新分配给拥有多元化製造地的供应商。

多维度細項分析表明，服务类型、交付管道、所有权结构、支付模式和最终用户如何共同决定策略重点和营运选择。

细分市场层面的趋势揭示了不同服务类型、交付管道、所有权模式、支付机制和最终用户群所面临的独特策略机会和营运挑战。在服务类型方面，随着临床通讯协定的调整和医疗机构对手术全期物流的优化，门诊手术服务正朝着更高吞吐量和当日手术路径发展。诊断影像服务正围绕影像模式的专业化进行重组。 CT、PET 和 X 光等电离辐射成像显像模式继续支持急性诊断和介入指导，而 MRI 和超音波等非电离辐射显像模式则在慢性病管理和照护现场决策支援方面发挥越来越重要的作用。透析服务正在努力平衡中心透析需求与居家透析模式和技术辅助监测的成长。居家医疗服务正在整合远距监测、专业护理支援和远端医疗分诊，以将护理延伸至患者家中。实验室服务正在优先考虑自动化、快速出结果和电子健康记录集成，以支援临床决策。远端医疗服务正从一次性虚拟咨询发展为连结专科医生和基层医疗机构的连续性照护模式。

区域分析：探讨美洲、欧洲、中东和非洲以及亚太地区之间的差异如何影响策略重点、监管方式和服务提供模式。

区域趋势导致法规环境、患者期望和医疗服务系统有显着差异，进而影响第三方医疗服务提供者之间的竞争与合作。美洲的市场结构特点是拥有先进的临床基础设施和多元化的支付模式，同时私部门的参与度不断提高，并专注于以患者为中心的门诊服务。投资往往集中于扩大门诊手术和先进影像技术，而居家照护也随着人口结构的变化而发展。

竞争行为分析：利用联盟、能力投资和选择性整合来扩大规模并提供综合临床服务

第三方医疗保健领域的活动以策略联盟、针对性投资以拓展能力以及选择性整合为特征，旨在扩大规模并提升专业水平。领先机构优先考虑跨领域合作，将临床能力与数位平台结合，以实现更整合的患者诊疗路径和一致的品质标准。併购活动的目标是互补资产，例如诊断连锁机构、实验室网路和居家照护平台，以建立多站点布局并简化转诊流程。

为领导者提供切实可行的优先建议，以增强韧性、加速整合，并使商业模式与不断变化的支付方和患者期望保持一致。

产业领导者必须采取策略行动，在短期营运稳定与长期能力建设和合作伙伴生态系统发展之间取得平衡。首先，他们应优先增强采购韧性，具体措施包括：透过供应商关係多元化和评估资本设备的总拥有成本，降低政策和供应链衝击带来的风险。同时，也应有针对性地投资于模组化、可升级技术，以延长设备使用寿命，并在无需大规模资本重新配置的情况下实现产能的逐步扩张。

我们将透明地解释用于收集专家见解、检验假设以及进行细分和地理分析的定性和三角调查方法。

本报告的调查方法结合了定性专家访谈、与关键相关人员的面对面交流，以及对已发表的政策文件和临床文献的系统性综合分析。主要资料收集工作包括与来自门诊、诊断和居家医疗机构的营运负责人、采购专业人员和支付方代表进行对话，以深入了解实际营运挑战、合约偏好和技术采纳模式。专家见解与监管文件、临床指南和供应商产品资料的二次分析相结合，以检验功能并为策略性倡议提供背景资讯。

一份简洁明了、结论性的综合报告，强调了临床能力、采购和支付方参与的策略协同如何确保营运韧性和竞争优势。

总之，第三方医疗服务提供者在现代医疗保健领域占据着战略前沿，提供必要的医疗能力、专科服务和灵活的诊疗路径，以满足不断变化的人口结构和患者日益增长的期望。技术、监管和支付方奖励机制的结构性转变正促使医疗服务提供者重组服务提供模式、优化采购流程并加强与整个医疗服务链的伙伴关係。积极投资于互通性、供应链韧性和结果衡量的机构将更有能力应对市场波动，并与支付方和医疗系统签订永续的合约。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：按服务类型分類的第三方医疗保健市场

  • 门诊手术服务
  • 诊断影像服务
    • 电离辐射成像
      • CT
      • PET
      • X射线
    • 非电离辐射成像
      • MRI
      • 超音波
  • 透析服务
  • 居家医疗服务
  • 检查服务
  • 远端医疗服务

第九章：按服务类型分類的第三方医疗机构市场

  • 居家医疗
  • 住院治疗
  • 门诊治疗

第十章：按所有权类型分類的第三方医疗保健市场

  • 私营营利企业
  • 私营非营利组织
  • 民众

11. 按支付模式分類的第三方医疗保健市场

  • 综合支付
  • 固定利率支付
  • 计量型

第十二章：以最终用户类型分類的第三方医疗保健市场

  • 诊所
  • 医院
  • 病人

第十三章：各地区的第三方医疗保健市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 第三方医疗保健市场（依集团划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国第三方医疗保健市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国第三方医疗保健市场

第十七章：中国第三方医疗机构市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • ACM Global Laboratories
  • ARUP Laboratories, Inc.
  • BioReference Laboratories, Inc.
  • Cerba Research SAS
  • Charles River Laboratories International, Inc.
  • Eurofins Scientific SE
  • ICON Public Limited Company
  • Laboratory Corporation of America Holdings
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories, Inc.
  • PPD, Inc.
  • Quest Diagnostics Incorporated
  • Sonic Healthcare Limited
  • Synlab International GmbH
Product Code: MRR-92740D85F099

The Third-party Medical Institutions Market was valued at USD 7.43 billion in 2025 and is projected to grow to USD 8.07 billion in 2026, with a CAGR of 8.91%, reaching USD 13.52 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.43 billion
Estimated Year [2026] USD 8.07 billion
Forecast Year [2032] USD 13.52 billion
CAGR (%) 8.91%

An authoritative orientation that frames the strategic importance, scope, and stakeholder relevance of third-party medical institutions in modern healthcare delivery

The contemporary healthcare environment is marked by accelerating change, where third-party medical institutions play an increasingly pivotal role in extending capacity, enabling specialty services, and supporting integrated care pathways. This introduction frames the strategic purpose of the research by clarifying the report's orientation toward stakeholders who manage or rely on outsourced clinical services, diagnostic platforms, home-based care delivery, and alternative payment arrangements. It articulates the need for high-quality, actionable intelligence that supports procurement strategy, partnership evaluation, and operational design across a spectrum of provider and payer settings.

Contextualizing the study, the report emphasizes the convergence of technological innovation, regulatory shifts, and shifting patient expectations that are reshaping how care is delivered and purchased. Analysts and executives will find that the report synthesizes qualitative insights from provider leaders, payers, and supply chain specialists, and interprets policy developments relevant to third-party institutional models. It also identifies the structural levers that institutions can use to enhance resilience, improve patient access, and optimize cost-efficiency without sacrificing clinical quality.

Throughout this introduction, the intent is to orient readers to the report's scope and to clarify how subsequent sections will unpack market dynamics, segmentation-based insights, regional variations, corporate activity, and practical recommendations. By establishing a clear narrative thread, the introduction prepares readers to move seamlessly from high-level trends into deeper analysis and operationally focused guidance.

A comprehensive analysis of the structural and technological forces reshaping third-party care providers and how these forces redefine clinical and business models

The healthcare landscape is undergoing transformative shifts driven by technological adoption, policy evolution, and changing patient expectations, and these shifts are altering the operating model for third-party medical institutions. One major vector of change is the normalization of virtual and remote modalities, which is expanding the remit of telemedicine and home healthcare services while compelling diagnostic and ambulatory providers to integrate digital workflows and remote monitoring into core service delivery. Concurrently, diagnostic imaging advances are increasing the clinical utility of non-invasive modalities, which is reshaping referral patterns and investment priorities across outpatient and inpatient settings.

Regulatory and reimbursement changes are also redefining incentives. New payment arrangements and value-based contracting models are motivating third-party providers to demonstrate care coordination capabilities, measurable outcomes, and cost management. As a result, providers are forming tighter partnerships with hospitals, clinics, and payer networks to manage care across settings. Supply chain resilience and procurement agility have moved to the top of the agenda; providers are diversifying sourcing strategies and adopting modular equipment procurement to reduce operational risk.

Workforce dynamics present another critical axis of transformation. Shortages of specialized staff and rising labor costs are accelerating the adoption of task-shifting models, remote interpretation services, and automation in laboratory and imaging workflows. These operational adaptations are enabling institutions to maintain service volumes while addressing quality and safety standards. Lastly, patient expectations around convenience, transparency, and outcome visibility are prompting providers to redesign the patient journey, with greater emphasis on outpatient access, rapid diagnostics, and integrated digital touchpoints that support continuity of care across the provider network.

An evidence-based evaluation of how recent U.S. tariff measures have influenced procurement, supplier strategies, and capital planning across outsourced clinical service providers

Recent tariff policies enacted by the United States have had a cumulative impact across supply chains, procurement economics, and strategic sourcing decisions for institutions that rely on cross-border medical equipment, consumables, and technical services. The aggregate effect is not limited to price adjustments; tariffs have propagated through procurement timelines, supplier relationships, and capital investment planning. In response, institutions and their vendor partners have accelerated supply chain risk assessments and are reallocating procurement priorities toward suppliers with diversified manufacturing footprints.

These tariff effects have influenced capital equipment acquisition strategies, particularly for diagnostic imaging and laboratory instrumentation where lead times and technical support are critical. Procurement officers are increasingly factoring total cost of ownership and service continuity into vendor selection, and are seeking instruments with modular upgrade paths to avoid frequent capital outlays. At the same time, tariffs have incentivized consideration of nearshoring and regional manufacturing partnerships to reduce exposure to policy volatility and to shorten replenishment cycles.

Policy-driven cost pressures are also reshaping commercial negotiations between third-party providers and payers. Service contracts now more frequently include clauses that address input-cost variability and incorporate shared-risk elements to protect both providers and purchasers. Moreover, these trade measures have prompted companies to reassess global distribution models and to explore localized service networks that preserve clinical availability while managing operating margins. Taken together, tariff-related dynamics are prompting an industry-wide emphasis on procurement agility, supplier diversification, and resilient service models that prioritize continuity of patient care.

A multifaceted segmentation analysis showing how service types, delivery channels, ownership structures, payment models, and end users collectively determine strategic priorities and operational choices

Segment-level dynamics reveal differentiated strategic opportunities and operational challenges across service types, delivery channels, ownership models, payment mechanisms, and end users. Within service type, ambulatory surgery services are evolving toward higher throughput and same-day care pathways as clinical protocols adapt and as facilities optimize perioperative logistics. Diagnostic imaging services are being reconfigured around modality specialization; ionizing imaging modalities such as CT, PET, and X ray continue to support acute diagnostics and interventional guidance, while non-ionizing imaging modalities including MRI and ultrasound are expanding their roles in chronic disease management and point-of-care decision support. Dialysis services are balancing in-center demand with the growth of home-based modalities and technology-enabled monitoring. Home healthcare services are integrating remote monitoring, skilled nursing support, and telehealth triage to extend care into the patient's home. Laboratory services are prioritizing automation, rapid turnaround, and connectivity to electronic health records to support clinical decision-making. Telemedicine services are maturing from episodic virtual visits to longitudinal care models that coordinate across specialists and primary care.

Delivery channels influence how services are accessed and reimbursed. Home care pathways are enabling chronic disease management and post-acute recovery outside institutional walls, whereas inpatient delivery remains the backbone for acute care and complex interventions, and outpatient settings are increasingly the locus for diagnostics and minor procedures that were previously confined to hospitals. Ownership models shape capital allocation and strategic priorities; private for-profit entities often prioritize operational efficiency and growth through scale, private non-profit operators tend to emphasize community outcomes and integrated partnerships with local health systems, and public ownership brings policy-driven mandates and broader population health responsibilities. Payment models exert a strong influence on provider behavior: bundled payments encourage integrated episode-based coordination, capitation incentivizes preventive care and population health management, and fee for service continues to underpin procedural volume economics and per-service reimbursement strategies. End user types drive service design and commercial approaches; clinics focus on workflow efficiency and referral management, hospitals prioritize throughput and inpatient-outpatient integration, and patients demand convenience, transparency, and measurable clinical benefit.

Taken together, these segmentation axes underscore the necessity for providers and partners to adopt differentiated strategies. Some institutions will strengthen modality-specific centers of excellence, others will expand home and outpatient offerings, and many will blend ownership-aligned governance with payment-sensitive contracting to remain competitive. Consequently, segmentation-aware strategy development is essential for aligning capital, talent, and technology investments with patient needs and reimbursement realities.

A regional synthesis highlighting how Americas, Europe Middle East & Africa, and Asia-Pacific variations shape strategic priorities, regulatory approaches, and service delivery models

Regional dynamics introduce significant variability in regulatory environments, patient expectations, and provider ecosystems, which in turn affect how third-party medical institutions compete and collaborate. In the Americas, the market is characterized by a mix of advanced clinical infrastructure and diverse payer models, with strong private sector participation and growing emphasis on patient-centered outpatient care. Investment flows often target capacity expansion for ambulatory surgery and advanced imaging, while home-based services are scaling in response to demographic pressures.

In Europe, the Middle East & Africa, healthcare systems vary widely from centralized public provision to mixed-market models, and this diversity affects provider incentives and partnership structures. Regulatory frameworks in several European markets favor interoperability and outcomes measurement, which encourages integration between third-party providers and national health systems. Across the Middle East and Africa, infrastructure gaps and workforce constraints create opportunities for third-party institutions to deliver scalable diagnostic and laboratory services, often in partnership with international technology providers.

The Asia-Pacific region presents a heterogeneous landscape where rapid urbanization, technological adoption, and a rising middle class are driving demand for convenient, high-quality care. Public and private players are investing in outpatient networks and home care capabilities, and digital health adoption is accelerating service delivery innovation. Across these regions, cross-border collaboration, regional supply chains, and regulatory harmonization initiatives are increasingly important considerations for institutions planning expansion or partnerships. Ultimately, region-specific strategies that account for payer mix, regulatory nuance, and population health priorities will be critical for sustained growth and operational resilience.

An examination of competitive behavior showing how partnerships, capability investments, and selective consolidation are being used to build scale and deliver integrated clinical services

Corporate activity in the third-party medical institution landscape is marked by strategic partnerships, targeted investments in capability expansion, and selective consolidation to gain scale or specialized expertise. Leading organizations are prioritizing cross-sector alliances that combine clinical capacity with digital platforms, thereby enabling more integrated patient pathways and consistent quality standards. Merger and acquisition activity often targets complementary assets such as diagnostic chains, laboratory networks, or home care platforms to create multi-site operational footprints and to streamline referral flows.

Investment priorities center on technology-enabled service delivery, with capital directed toward imaging upgrades that improve diagnostic yield, laboratory automation that reduces turnaround time, and telehealth platforms that support continuity of care. Strategic investors and corporate development teams are also allocating resources to build or acquire expertise in regulatory compliance, outcomes measurement, and payer contracting, recognizing that these capabilities are essential for value-based arrangements. In addition, some companies are experimenting with service bundles and managed care partnerships that align incentives across episodes of care and that extend the provider's role into population health management.

Competitive differentiation increasingly relies on demonstrable clinical outcomes, operational reliability, and the ability to integrate with broader care ecosystems. Firms that combine clinical excellence with predictable service delivery, transparent pricing, and robust data interoperability are positioned to secure long-term contracts with health systems and payers. As a result, corporate strategies are converging on the dual objectives of expanding service breadth while deepening technical and contractual capabilities that support accountable care models.

Practical and prioritized recommendations for how leaders can strengthen resilience, accelerate integration, and align commercial models with evolving payer and patient expectations

Industry leaders must adopt strategic actions that balance near-term operational stability with longer-term investments in capability and partner ecosystems. First, leaders should prioritize strengthening procurement resilience by diversifying supplier relationships and assessing total cost of ownership for capital equipment, thereby reducing exposure to policy and supply-chain shocks. This should be complemented by targeted investments in modular, upgradeable technologies that extend equipment lifecycles and enable incremental capability expansions without major capital redeployments.

Second, organizations should accelerate digital integration across service lines to ensure data flows seamlessly between diagnostic, ambulatory, home care, and telemedicine venues. Interoperability investments will improve care coordination, enable more effective outcomes measurement, and support value-based contracting. Third, payment-model flexibility is essential; providers should develop contracting playbooks for bundled payments and capitation while retaining operational pathways to serve fee-for-service arrangements. This dual capability will allow providers to tailor offerings to payer needs and to negotiate risk-sharing arrangements with confidence.

Fourth, workforce strategies must emphasize both retention and skill mix optimization. Leaders should invest in remote interpretation, task-shifting models, and continuous education programs to mitigate specialist shortages and to enhance productivity. Fifth, regional expansion should be pursued with careful regulatory due diligence and partner selection; local partnerships and joint ventures can accelerate market entry while mitigating compliance and cultural risks. Finally, leaders should embed outcomes-focused performance metrics into commercial negotiations and internal governance to align incentives across clinicians, administrators, and payers. These measures together will help institutions remain responsive to demand shifts and resilient in the face of external disruptions.

A transparent description of the qualitative and triangulated research methods used to gather expert insight, validate assumptions, and structure the segmentation and regional analyses

The research methodology underpinning this report combines qualitative expert interviews, primary stakeholder engagement, and a structured synthesis of publicly available policy and clinical literature. Primary data collection included conversations with operational leaders in ambulatory, diagnostic, and home-based care settings, procurement specialists, and payer representatives to capture real-world perspectives on operational challenges, contracting preferences, and technology adoption patterns. Expert inputs were triangulated with secondary analysis of regulatory filings, clinical guidelines, and vendor product documentation to verify capabilities and to contextualize strategic moves.

Analytical approaches emphasized cross-validation and scenario analysis to test how different regulatory and supply-chain conditions might influence provider responses. Segmentation analysis was conducted by mapping service types, delivery channels, ownership models, payment frameworks, and end-user categories to observed behaviors and strategic choices. Regional assessments drew on policy reviews and stakeholder interviews to identify distinctive drivers and constraints in the Americas, Europe Middle East & Africa, and Asia-Pacific. Care was taken to ensure methodological transparency by documenting data sources, interview protocols, and analytical assumptions in the report appendices.

Limitations of the methodology were acknowledged, including the inherent variability in policy landscapes and the evolving nature of technology adoption. To mitigate these limitations, the methodology incorporated iterative validation with subject-matter experts and sensitivity checks that explored how different operational priorities influence strategic outcomes. The result is a robust qualitative foundation that supports practical recommendations and helps decision-makers interpret how macro trends are likely to play out across different institutional contexts.

A concise concluding synthesis that reinforces how strategic alignment across clinical capabilities, procurement, and payer engagement secures operational resilience and competitive advantage

In conclusion, third-party medical institutions occupy a strategic frontier in contemporary healthcare, providing essential capacity, specialized services, and flexible care pathways that respond to demographic change and evolving patient expectations. Structural shifts in technology, regulation, and payer incentives are prompting providers to reconfigure service delivery, optimize procurement, and strengthen partnerships across the care continuum. Those organizations that proactively invest in interoperability, supply chain resilience, and outcomes measurement will be better positioned to navigate volatility and to secure durable contracts with payers and health systems.

Operationally, the interplay between modality specialization, delivery channel optimization, and payment-model agility will determine competitive positioning. Leaders who align capital investments with segmentation-specific strategies and who pursue regionally tailored expansion plans can balance growth with operational resilience. By embedding performance metrics into governance and by negotiating contracts that reflect input-cost variability, providers can build sustainable models that preserve quality while managing financial risk. The overall imperative is clear: integrate clinical excellence with commercial discipline to deliver care that is accessible, reliable, and demonstrably effective.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Third-party Medical Institutions Market, by Service Type

  • 8.1. Ambulatory Surgery Services
  • 8.2. Diagnostic Imaging Services
    • 8.2.1. Ionizing Imaging
      • 8.2.1.1. CT
      • 8.2.1.2. PET
      • 8.2.1.3. X Ray
    • 8.2.2. Non Ionizing Imaging
      • 8.2.2.1. MRI
      • 8.2.2.2. Ultrasound
  • 8.3. Dialysis Services
  • 8.4. Home Healthcare Services
  • 8.5. Laboratory Services
  • 8.6. Telemedicine Services

9. Third-party Medical Institutions Market, by Delivery Channel

  • 9.1. Home Care
  • 9.2. Inpatient
  • 9.3. Outpatient

10. Third-party Medical Institutions Market, by Ownership Model

  • 10.1. Private For Profit
  • 10.2. Private Non Profit
  • 10.3. Public

11. Third-party Medical Institutions Market, by Payment Model

  • 11.1. Bundled Payments
  • 11.2. Capitation
  • 11.3. Fee For Service

12. Third-party Medical Institutions Market, by End User Type

  • 12.1. Clinics
  • 12.2. Hospitals
  • 12.3. Patients

13. Third-party Medical Institutions Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Third-party Medical Institutions Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Third-party Medical Institutions Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Third-party Medical Institutions Market

17. China Third-party Medical Institutions Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. ACM Global Laboratories
  • 18.6. ARUP Laboratories, Inc.
  • 18.7. BioReference Laboratories, Inc.
  • 18.8. Cerba Research S.A.S.
  • 18.9. Charles River Laboratories International, Inc.
  • 18.10. Eurofins Scientific SE
  • 18.11. ICON Public Limited Company
  • 18.12. Laboratory Corporation of America Holdings
  • 18.13. Myriad Genetics, Inc.
  • 18.14. NeoGenomics Laboratories, Inc.
  • 18.15. PPD, Inc.
  • 18.16. Quest Diagnostics Incorporated
  • 18.17. Sonic Healthcare Limited
  • 18.18. Synlab International GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY AMBULATORY SURGERY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY AMBULATORY SURGERY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY AMBULATORY SURGERY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY X RAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY X RAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY X RAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIALYSIS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIALYSIS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIALYSIS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY HOME HEALTHCARE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY HOME HEALTHCARE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY HOME HEALTHCARE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY LABORATORY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY LABORATORY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY LABORATORY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY TELEMEDICINE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY TELEMEDICINE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY TELEMEDICINE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PRIVATE FOR PROFIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PRIVATE FOR PROFIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PRIVATE FOR PROFIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PRIVATE NON PROFIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PRIVATE NON PROFIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PRIVATE NON PROFIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY BUNDLED PAYMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY BUNDLED PAYMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY BUNDLED PAYMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY CAPITATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY CAPITATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY CAPITATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY FEE FOR SERVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY FEE FOR SERVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY FEE FOR SERVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. GCC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GCC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. GCC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 171. GCC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 172. GCC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 173. GCC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. GCC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 175. GCC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 176. GCC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. G7 THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. G7 THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. G7 THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 198. G7 THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 199. G7 THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 200. G7 THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. G7 THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 202. G7 THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 203. G7 THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. NATO THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. NATO THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. NATO THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 207. NATO THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 208. NATO THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 209. NATO THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. NATO THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 211. NATO THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 212. NATO THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)